RxDoctor Payments DataLook up a doctor →

Jacqueline Graziani

Gerontology · Lorain, OHNPI 1861823676

Payments from drug & device makers

$44,263in general payments, 2019–2025

Across 661 payments — averaging $66.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biohaven Pharmaceutical Holding Company Ltd.$17K
  • Biohaven Pharmaceuticals, Inc.$16K
  • AbbVie$3K
  • Livanova USA, Inc.$2K
  • EMD Serono, Inc.$648
  • Biogen$595
  • plus $6K from 43 others

What the payments were for

  • Consulting fees$5001%
  • Speaking & faculty fees$26,70060%
  • Travel & lodging$4,43610%
  • Food & beverage$12,62729%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$44,263 in reported general payments places this provider in the 95th percentile of 361 gerontology providers in Ohio.

See all gerontology providers in Ohio

Medicare billing

Part B allowed, 2024
$160,226
Medicare patients
187
Services billed
24,437

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5020$106,479
BotoxOnabotulinumtoxina49$81,979
Nurtec OdtRimegepant Sulfate35$70,267
UbrelvyUbrogepant35$46,746
Aimovig AutoinjectorErenumab-Aooe29$36,045
Emgality PenGalcanezumab-Gnlm41$32,785
Ajovy AutoinjectorFremanezumab-Vfrm16$30,517
NuedextaDextromethorphan Hbr/Quinidine15$28,387
QuliptaAtogepant20$27,769
XcopriCenobamate14$21,918
Atomoxetine Hcl52$10,454
SavellaMilnacipran Hcl12$6,253
Oxcarbazepine77$5,016
Droxidopa20$4,371
AmantadineAmantadine Hcl71$3,118

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieBotox, Ubrelvy, Qulipta, Savella$3,055$162,747116 claims
Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid$30$106,47920 claims
PfizerNurtec Odt$227$70,26735 claims
SK Life Science, Inc.Xcopri$201$21,91814 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 361 gerontology providers in Ohio.

Other gerontology in Lorain

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →